An initial safety study of Gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer

Study Overview

Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer.

Study Description

The purpose of this study is to evaluate the safety of Gedatolisib plus PTK7-ADC in patients with metastatic triple-negative or estrogen poor breast cancer as assessed by NCI CTC v4.0 criteria.

Additional Information

Participants will not be paid for their participation.

  • IRB Number: 1704239900 (IUSCC-0613)
  • Research Study Identifier: TX7919
  • Principal Investigator: Kathy Miller, MD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: or call us at (317) 278-2176